CyVek Inc. says
it will use $5.5 million in new financing to further develop the company’s immunoassay biomarker technology. The Series D round will enable CyVek to lay the groundwork for commercializing its CyPlex integrated test system, which features a microfluidic cartridge for analyzing very small sample amounts, the company says. The round was funded by Connecticut Innovations and private investors.
The CyPlex platform can be configured for a range of research and clinical applications, according to CyVek. These include rapid diagnostic tests, multi-sample tests for multiple analytes, and ELISA-like tests. Now in beta testing, the technology will initially be used for biomarker analysis in life sciences, drug discovery, and clinical research, CyVek says. Launched in 2010, the company is based in Wallingford, CT.